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ABSTRACT 
 
Several religions recommend periods of fasting. One of the most frequently asked 
questions of MS patients before the holy month of Ramadan is weather fasting might have 
an unfavorable effect on their disease course. This debate became more challenging after the 
publication of experimental studies suggesting that calorie restriction prior to disease 
induction attenuates disease severity. We conducted this study to assess early and late effects 
of fasting on the animal model of MS, known as autoimmune encephalomyelitis. 
EAE was induced in the C57BL/6 mice, using Myelin Oligodendrocyte Glycopeptide  
(MOG) 35-55 and they fasted every other day either after the appearance of the first clinical 
sign or 30 days after disease induction for ten days. Thereafter, the mice were sacrificed for 
further histological and immunological evaluations. 
Intermittent fasting after the establishment of EAE did not have any unfavorable effect 
on the course of disease. Moreover, fasting at the early phase of disease alleviated EAE 
severity by ameliorating spinal cord demyelination. Fasting suppressed the secretion of IFN-
γ, TNF-α and raised IL-10 production in splenocytes. Fasting was also associated with a 
lower percent of cytotoxicity. 
Intermittent fasting not only had no unfavorable effect on EAE but also reduced EAE 
severity if started at early phase of disease. 
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INTRODUCTION 
 
Several religions including Islam suggest times of 
fasting. Although sick Muslims are exempted from 
fasting, many individuals with mild, moderate, and 
severe medical conditions choose to fast. Furthermore, 
recent evidences suggest that there is no 
contraindication to Islamic fasting for patients with 
many of the type-2 diabetes, asymptomatic peptic 
ulcer, intestinal motility disorders, stable asthma, 
valvular problems and mild coronary artery disease.
1
 
Multiple sclerosis (MS) is one of these medical 
conditions. MS is a complex demyelinating syndrome 
with an unclear etiology that affects approximately 
two-and-a-half million individuals worldwide and is 
identified as the most common debilitating neurological 
disease in young adults.
2
 MS is an immune-mediated 
inflammatory disease of the central nervous system 
(CNS) that, in the most severe cases, can lead to 
irreversible clinical disability.
3
 The concern for Muslim 
MS patients is weather Ramadan fasting might have an 
unfavorable effect on their disease course. This issue 
became more conflicting after the work of Esquifino et 
al. on the animal model of MS, known as Experimental 
Autoimmune Encephalomyelitis (EAE). They reported 
that calorie restriction
4
 improves signs of EAE.
5
 Hence, 
we aimed to assess the possible impact of intermittent 
fasting (IF) on mice induced with EAE, either after the 
appearance of the clinical signs or after the 
establishment of the disease. 
 
 
MATERIALS AND METHODS 
 
Mice 
The study was performed on 8-12 week old female 
C57BL/6 mice, 6 mice per each group (Pasture 
Institute, Iran). The animals were maintained on a 12 
hour light-dark cycle. All study protocols were in 
accordance with Shefa neuroscience center guidelines 
for laboratory animals.  
 
EAE Induction 
The mice were immunized with a 1:1 ratio of MOG 
35-55 (Alexis, Switzerland) dissolved in complete 
Freund’s adjuvant (CFA) prepared from non-
metabolizable oil (paraffin oil and mannide 
monooleate) containing 0.4 mg of mycobacterium 
tuberculosis (Sigma-Aldrich, USA). For this purpose, 
300 μg of MOG was dissolved in 100 μl PBS 
(phosphate buffered saline 10%, Sigma-Aldrich, USA) 
and mixed with an equal volume of CFA. On day 0, the 
MOG-CFA emulsion was subcutaneously injected into 
two sites of the upper flanks (200 μg/mouse). The 
additional immune adjuvant, pertussis toxin (PTX), 
(Sigma-Aldrich, USA) was injected intraperitoneally 
(IP) (400 ng/mouse) on days 0 and 2.
6
  
 
Administering with IF  
The effect of intermittent fasting on EAE severity was 
assessed at two stages of the disease. In the first 
experiments, the mice were either fed every other day 
 
 
day 0     10     21     30     40  
IF-1            ×           
         IF              
Control-1            ×           
                       
IF-2                      × 
                  IF     
Control-2                      × 
 
Figure 1. The schematic chart for EAE induction and treatment of female C57BL/6 mice with intermittent fasting (IF). The 
first clinical sign of EAE appeared between days 9 and 11 in the IF-1 group (10±0.89). Mice in this group were fed every 
other day after the appearance of the first clinical sign for 10 days. Mice in the control-1 group continued daily feeding for 21 
days. The IF-2 group was put on intermittent fasting from 30 days post-immunization for 10 days. The control-2 group 
continued daily feeding for 40 days. All mice were sacrificed for further assessments, one day after the last treatment. 
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after the appearance of the first clinical sign for 10 days 
(IF-1) or daily with normal rodent chew for 21 days 
(control-1). In the second experiment, the mice were 
either put on IF from 30 days post-immunization for 10 
days (IF-2) or fed daily for 40 days (control-2). Rodent 
chew contained: 17.5% protein, 2% fat, 12% fiber, 12% 
water, and 56.5% carbohydrate. Mice in the IF groups 
were subjected to fasting every other day (from 10 AM, 
for 24 hours). Figure 1 shows the schematic chart for 
EAE induction. 
 
Clinical Evaluation of EAE 
The clinical scores were recorded daily in  
all studied groups. In the IF-1 group, daily recording  
of the clinical scores of each mouse started on day  
0 and continued for 10 days after the onset of the 
clinical signs. In the IF-2 group, daily scoring 
continued for 40 days. The following grading scheme 
was applied to score the clinical signs of EAE: 0 for  
no clinical signs, 0.5 hook tail, 1 flaccid/floppy tail,  
2 walking deficits, 2.5 unilateral hind limb paralysis,  
3 bilateral hind limb paralysis, 3.5 paraplegia  
with forelimb weakness, 4 quadriplegia, and 5 for 
moribund. The Clinical examiners were not blind to the 
treatment. 
 
Histological Evaluations 
At the end of the experiment, cervical dislocation 
(CD) method was used for animal scarification. 
Immediately after CD with a longitudinal section on 
midline of animal body, we had access to the vertebral 
column. The vertebral column was removed from the 
body and the spinal cord was extracted using a bone 
crusher. The tissues were fixed with paraformaldehyde 
4% for 24 hours; then, they were transferred to the 
tissue processor device (Payroll process), and after 
dehydration and clearing, they were embedded in 
paraffin. Axial lumbar spinal cord sections (8 microns) 
were cut using rotary cryostat. A series of 4-5 cuts were 
mounted on one slide using albumin glue. The samples 
were stained with Luxol Fast Blue (Merck, 
Germany)/Cresyl violet (BDH, England) for assessing 
the demyelination.  
 
Spleen Cytokine Concentration 
At the end of the experiment, the spleen of the mice 
were dissected and homogenized to obtain single cell 
suspensions. Mononuclear cells were suspended in 1.5 
ml of RPMI-1640 (Gibco-BRL, UK) supplemented 
with 10% FCS (Gibco), 1% L-glutamine, 1% HEPES, 
0.1% 2ME, and 0.1% penicillin/streptomycin, and were 
incubated at the concentration of 2 × 10
6
 cells/well in 
24-well plates (Nunc, Denmark) for 2 days at 37 oC in 
5% CO2  and 90% humidity incubator. The cells were 
then pulsed with MOG 35-55. Cell supernatants were 
then collected and analyzed for the presence of 
cytokines using commercially available sandwich-
based ELISA kits according to the manufacturer’s 
protocol (eBioscience, USA). All tests were performed 
in triplicate for each mouse. 
 
Lymphocyte Proliferation Assay 
At the end of the experiment, mononuclear cells 
were obtained from the treated mice and were used for 
the assay. Briefly, the suspension of isolated spleen 
cells was treated with lyses buffer 0.15 M NH4Cl, 1 
mM KHCO3, 0.1 mM Na2EDTA, (pH 7.2)]. 2 × 10
5
 
cells/well were cultured in 96-well flat-bottom culture 
plates (Nunc, Denmark). The preparations were 
cultured with RPMI-1640, supplemented with 10% 
fetal calf serum, 1% L-glutamine, 1% HEPES, 0.1% 
2ME, 0.1% penicillin/streptomycin, and were incubated 
in the presence of 1 µg/ml MOG. T-cell mitogen PHA 
(phytohemagglutinin, Sigma chemicals) at the 
concentration of 5µg/ml was used as positive control. 
After 3 days, MTT (3-(4,5-dimethyl tetrazolyl-2) 2, 5 
diphenyltetrazolium bromide) (Sigma chemicals, 
Australia) at the concentration of 5 µg/ml was added 
per well and incubated for 5 hours at 37 
o
C in 5% CO2  
and 90% humidity incubator. DMSO (dimethyl 
sulfoxide) (100 µl) was added to dissolve the produced 
formazan crystals. 
The plates were read at 540 nm using ELISA 
method and intensity of the color reaction product was 
quantitated on a microplate reader (ELx800, Biotek 
Instruments, Inc., Winooski, VT, USA). The results 
were expressed as stimulation index (SI). The SI was 
determined as follows: OD values of stimulated cells 
(Cs) minus relative cell numbers of unstimulated cells 
(Cu) divided by relative OD values of unstimulated 
cells: SI=(Cs-Cu)/Cu 
All tests were performed in triplicate for each 
mouse.  
 
Data Analysis 
Parametric variables were assessed using 
independent sample T-test with Levene’s Test for 
checking the equality of variances. Mann-Whitney U 
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Test was used to compare non-parametric variables. 
Differences were considered significant at p<0.05. Data 
were analyzed with SPSS version 17. 
 
RESULTS 
 
Clinical Assessments 
After the induction of EAE, female C57BL/6 mice 
were fasted every other day in early (IF-1), and late 
phases (IF-2) of the disease. Fasting every other day in 
the late phase of disease had no significant effect on the 
mean and maximum clinical score of the disease 
(Figure 2). Moreover, mice that fasted every other day 
in the early phase of the disease showed significantly 
lower scores between days 15 and 21 post induction 
(p<0.05).  
 
 
Histological Evaluations 
On the day after receiving the last treatment, the mice 
were sacrificed, and their spinal cords were removed. As 
presented in Figure 3, demyelinated lesions were 
apparent in the white matter of the spinal cord of the 
controls and the IF-2 group. A lack of demyelinated foci 
in spinal cord was observed in IF-1 animals. 
 
Cytokine Assay 
One day after receiving the last treatment, the 
spleens of the mice were removed. The level of IFN-γ, 
TNF-α, IL-10, and IL-12 were assessed in splenocytes. 
Intermittent fasting in the early phase of the disease 
decreased IFN-γ and TNF-α levels and enhanced IL-10 
production in comparison to the control group. No 
significant differences were observed between IF-2 and 
control groups (Figure 4). 
 
 
AA 
A-1       A-2 
B 
 Control-1 IF-1 p value  Control-2 IF-2 p.value 
Incidence 5/6 6/6 0.3‡  6/6 6/6  
Day of onset 10.25±0.96 10±0.89 0.76¥  14±1.54 14±3.35 0.81¥ 
Maximum 
clinical score† 
2.87 (2-4) † 1.58 (0.5-2.5) † 0.067¥  2.58 (1-3) † 2.42 (1-3) † 0.48¥ 
Figure 2. Clinical signs of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice administered with IF for 10 
days either after the appearance of the first clinical sign or 30 days post immunization. A) The mean daily clinical scores of 
IF-1 animals were significantly lower than the control group between days 15 and 21 post immunization (p<0.05). B); also, 
IF-1 mice had a lower maximum disease scores (p= 0.048) compared to the control group. The data represents as mean±SD. 
†) mean score (minimum-maximum), ‡ level of significance using Pearson Chi-square Test, ¥ level of significance using 
Mann-Whitney U Test. IF-1: Intermitted Fasting after the appearance of first clinical sign, IF-2: Intermitted Fasting from 30 
days post immunization, Control-1: normal chew for 21 days, Control-2: normal chew for 40 days. 
 
Treated with IF 
* 
Treated with IF 
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Control-1   IF-1 
      
Control-2   IF-2 
      
 
Figure 3. Demyelination of the spinal cords in mice induced with experimental autoimmune encephalomyelitis and treated 
with IF or continued daily feeding. Luxol Fast Blue/ Cresyl violet staining was applied to assess the ratio of demyelination of 
spinal cord. Myelin became blue and demyelinated areas became violet. As shown in pictures above, demyelinated areas are 
apparent in the outer layer of the white matter of IF-2 and Control groups. IF-1: Intermitted Fasting after the appearance of 
the first clinical sign for 10 days, IF-2: Intermitted Fasting from 30 days post immunization for 10 days, Control-1: normal 
chew for 21 days, Control-2: normal chew for 40 days 
 
A           B 
 
Figure 4. Cytokines level (pg/ml) in splenocytes of experimental allergic encephalomyelitis (EAE) induced C57BL/6 mice. 
IFN-γ, TNF-α, IL-12, and IL-10 were measured in the supernatant of cultured splenocyte as described in methods. A) 
Intermittent fasting after the onset of clinical signs (IF-1) modified spleen level of IL-10, TNF-α and IFN-γ compared to the 
control group. All data were expressed as mean±SD *) p<0.05 in comparison to control-1and **) p<0.005 in comparison to 
control-1. IF-1: Intermitted fasting after the appearance of the first clinical sign, IF-2: Intermitted Fasting from 30 days post 
immunization, Control-1: normal chew for 21 days, Control-2: normal chew for 40 days. 
 
MTT Assay 
The mice were sacrificed 24-hours after the last 
treatment and the spleen cells were harvested. The 
lymphocytes were stimulated in-vitro by 1 µg/ml MOG 
and evaluated by MTT methods. As presented in Figure 
5, the proliferative response of T-cells was suppressed 
in IF-1 mice compared to the control group (p= 0.003). 
No significant difference was observed between IF-2 
mice and the control group. 
 
* * 
** 
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Figure 5. Lymphocyte proliferation response in control and intermittent fasting (IF) groups. The Intermittent fasting mice 
induced less specific proliferation response, in comparison to the control group. All data were expressed as mean±SD. *) 
p<0.05 in comparison to control-1. IF-1: Intermitted fasting after the appearance of first clinical sign, IF-2: Intermitted 
fasting from 30 days post immunization, Control-1: normal chew for 21 days, Control-2: normal chew for 40 days. 
 
 
DISCUSSION 
 
In this study, we showed that fasting every other 
day did not aggravate the EAE course. Furthermore, 
fasting in the early phase of the disease, notably 
alleviated the severity of the clinical signs of the 
disease, confirmed by less severe CNS pathology. 
Esquifino et al. have previously reported that daily 
calorie restriction
4
 attenuates EAE course in Lewis 
rats.
5,7
 They reported that restricting energy intake by 
33% or 66%,15 days prior to immunization decreased 
the severity of EAE.
7
 This was in accordance with the 
results of the current study. 
In the current study, we observed that IF, after the 
appearance of the first clinical signs, modified the 
immune response by lowering the level of IFN-γ, and 
elevating the level of IL-10 in cultured splenocytes. 
Moreover, IF diminished T-cell proliferation. Esquifino 
et al. reported impairment in lymphocyte proliferation, 
a decrease in CD4+ cells of lymphoid organs, and 
suppressed IFN-γ production, which was in agreement 
with our results.
5
 IFN-γ, which is predominantly 
secreted by T-cells and natural killer cells, 
differentiates T-cells from Th1 cells; activates 
macrophages, and microglia cells.
8
 The accumulated 
data pointed to the principal role of IFN-γ in 
progressive demyelinating diseases, including MS and 
EAE;
9
 IFN-γ becomes detectable in the CNS at the 
onset of EAE/MS. This cytokine is involved in many of 
the pathological features of MS/EAE
10,11
 and partial 
elimination of IFN-γ enhances tolerance to EAE.12 The 
systemic administration of IFN-γ to MS patients 
worsens the disease.
13
 One of the MS therapeutic 
effects attributed to IFN-β is the down-regulation of 
IFN-γ production.14  
Moreover, the increase in the level of IL-10 of 
splenocytes observed in the IF-1 group in the present 
study was in line with previous observations reporting 
that in overweight patients,
15
 and in experimental 
diabetes
16
 CR elevates IL-10 production. IL-10 is 
primarily secreted by Th2 cells, B cells and monocytes. 
IL-10 reduces the expression of MHC II and suppresses 
cytokine secretion by macrophages. This cytokine 
plays a unique role in recovering from EAE.
17
 Increase 
in cerebral IL-10 level was reported during the 
remission phase of MS.
9
 Treating Lewis rats with 
human recombinant IL-10 at the onset of the disease 
has prevented the incidence and decreased the severity 
of EAE.
18
 IL-10-deficent C57BL/6 mice are more 
prone to EAE development. They exhibit a more severe 
form of EAE.
19
 
We also showed that prescribing mice with IF at the 
onset of the disease decreased the secretion of TNF-α 
from splenocytes. In contrast to our results, in the study 
* 
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by Piccio et al. a 40% calorie restriction for 30 days did 
not lead to the suppression of TNF-α secretion from 
lymphoid tissues in EAE-induced C57BL/6 mice.
4
 
TNF-α is mainly secreted by activated T-cells, NK 
cells, and phagocytic cells.
9
 TNF-α injection led to the 
exacerbation of clinical signs and prolongation of the 
clinical course of EAE.
20
 TNF-α release parallels the 
disease course of EAE,
21
 and the maximum severity of 
EAE is between days 19 and 22.
22
 Therefore, the 
difference between our results and findings of Piccio et 
al. may in part be due to the time of assessing the 
cytokine profile, which was about 21 days post 
induction (p.i.) in the current study and 30 days p.i. in 
the research by Piccioet al. On the other hand, in 
agreement with our results, the decreasing effect of 
calorie restriction reduced TNF-α level in previous 
studies conducted on experimental diabetes
15 
as well as 
the animal model of immunity and inflammation.
2
 
Furthermore, the following mechanisms have been 
proposed for the beneficial effects of CR in 
experimental model of MS. First, CR can improve the 
function of immune system. Long-term CR modifies T-
cell function and delays immune senescence. Squifino 
et al. reported the favorable effect of 66% CR in 
modifying the lymph node mitogenic response to 
lipopolysaccaride and Concanavalin A. It also 
improved 24-hour rhytmicity of B, T, CD4+CD8+, and 
CD4+ lymph node cell subsets function.
5,6
 Moreover, 
CR resulted in the increment of the mean values of 
submaximally lymph node (SMLN) Con A response as 
well as the reduction of the number of B-cells.
7
 Second, 
CR could enhance glucocorticoids production. 
Glococorticoids showed inhibitory effects on the 
expression of inflammatory genes.
23
 Corticosteroid 
administration has been used as a standard therapy in 
MS relapse.
24
 In rodent, treating with exogenous 
glucocorticoids suppressed EAE.
24
 In Piccio et al. 
study, CR elevated corticostrone level.
4
 Notably, the 
endogenous production of corticostroides would 
prevent the side-effects of exogenouse administration 
of steroids.
4
 Adipose tissue can produce IL-6. CR 
decreased body fat and subsequently IL-6 level. IL-6 
together with TGF-β, were reported to restrain the 
production of T regulatory cells (T-regs), resulting in 
the inhibition of Th-17 gene expression.
4
 Expression of 
Th-17 is known as one of the key features of MS.
26
 We 
did not measure Th-17, which is one of the limitations 
of our study. Assessing the effect of CR on Th-17 and 
consequently granulocyte-macrophage colony-
stimulating factor (GM-CSF) production is warranted 
in future studies. In conclusion the fact that intermittent 
fasting after the onset of EAE attenuates disease 
severity, proposed the idea that fasting might dampen 
immune responses and alleviate EAE symptoms when 
applied at the early phase of the disease. Moreover, 
Fasting after the establishment of the disease had no 
unfavorable effect on EAE severity.  
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